Areteia Therapeutics introduces dexpramipexole, a novel oral drug in Phase 3 trials for asthma and COPD, aiming for approval ...

A multi-institutional study has identified one of the allergens responsible for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus. This is the first time one of the allergens ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., ...